Functional regulation of HIF-1α under normoxia-is there more than post-translational regulation?

Journal of Cellular Physiology

Volumn 227, Issue 2, 2012, Pages 514-524

  Kuschel, A ^a   Simon, P ^a   Tug, S ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CYCLIC AMP; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; SCATTER FACTOR; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CELL PROLIFERATION; CELL VIABILITY; HOMEOSTASIS; HUMAN; HYPOXIA; MELANOCYTE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMALS; OXYGEN;

EID: 82155192318     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22798     Document Type: Review

References (133)

1. Ambros V. 2004. The functions of animal microRNAs. Nature 431: 350-355.
2. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408.
3. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M. 2001. Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 42: 9-16.
4. Balkwill F. 2009. Tumor necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
5. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
6. Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233.
7. Beiter T, Reich E, Williams RW, Simon P. 2009. Antisense transcription: A critical look in both directions. Cell Mol Life Sci 66: 94-112.
8. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, Görlach A. 2007. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18: 4691-4697.
9. Bilton RL, Booker GW. 2003. The subtle side to hypoxia inducible factor (HIF alpha) regulation. Eur J Biochem 270: 791-798.
10. Blouin CC, Pagé EL, Soucy GM, Richard DE. 2004. Hypoxic gene activation by lipopolysaccharide in macrophages: Implication of hypoxia-inducible factor 1α. Blood 103: 1124-1130.
11. Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Michiels C, Kietzmann T, Görlach A. 2007. Reactive oxygen species activate the HIF-1α promoter via a functional NFkB site. Arterioscler Thromb Vasc Biol 27: 755-761.
12. Bracken CP, Whitelaw ML, Peet DJ. 2003. The hypoxia-inducible factors: Key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60: 1376-1393.
13. Brahimi-Horn C, Mazure N, Pouysségur J. 2004. Signalling via the hypoxia-inducible factor -1α requires multiple posttranslational modifications. Cell Signal 17: 1-9.
14. Brennan CM, Steitz JA. 2001. HuR and mRNA stability. Cell Mol Life Sci 58: 266-267.
15. Buscà R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribère L, Bertolotto C, Virolle T, Barbry P, Pouysségur J, Ponuio G, Ballotti R. 2005. Hypoxia-inducible factor-1alpha is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170: 49-59.
16. Calin GA, Ferracin M, Cimmino A, DiLeva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
17. Cha ST, Chen PS, Johannson G, Chu CY, Wang MY, Jeng YM, Yu SL, Chen JS, Chang KJ, Jee SH, Tan CT, Lin MT, Kuo ML. 2010. MircoRNA-519c suppresses hypoxia-inducible factor-1α expression and tumor angiogenesis. Cancer Res 70: 2675-2685.
18. Chan DA, Sutphin PD, Yen SE, Giaccia AJ. 2005. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25: 6415-6426.
19. Chang LH, Chen CH, Huang DY, Pai HC, Pan SL, Teng CM. 2010. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells. J Cell Physiol 226: 1060-1068.
20. Chen CZ. 2005. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771.
21. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420: 860-867.
22. Dinarello CA. 2006. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 25: 307-313.
23. Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC. 2001. Microphthalmia transcription factor: A sensitive and specific marker for malignant melanoma in cytologic specimens. Cancer 93: 337-343.
24. Edwards RL, Klaus M, Matthews E, McCullan C, Bona RD, Rickles FR. 1990. Heparin abolishes the chemotherapy-induced increase in fibrinopetide A levels. Am J Med 89: 25-28.
25. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
26. Fandrey J, Gorr TA, Gassmann M. 2006. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res 71: 642-651.
27. Fausto N. 1991. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 3: 219-234.
28. Frede S, Stockmann C, Freitag P, Fandrey J. 2006. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kB. Biochem J 396: 517-527.
29. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211.
30. Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D, Sandaltzopoulus R. 2008. Reactive oxygen species and HIF-1 signaling in cancer. Cancer Lett 266: 12-20.
31. Galbán S, Gorospe M. 2009. Factors interacting with HIF-1α mRNA: Novel therapeutic targets. Curr Pharm Des 15: 3853-3860.
32. Gillespie MT, Horwood NJ. 1998. Interleukin-18: Perspectives on the newest interleukin. Cytokine Growth Factor Rev 9: 109-116.
33. Gong Q, Quan J, Jiang H, Ling J. 2010. Regulation of the stromal cell-derived factor-1α- CXCR4 axis in human dental pulp cells. J Endod 36: 1499-1503.
34. Görlach A. 2009. Regulation of HIF-1alpha at the transcriptional level. Curr Pharm Des 15: 3844-3852.
35. Görlach A, Bonello S. 2008. The cross-talk between NF-kB and HIF-1: Further evidence for a significant liaison. Biochem J 412: e17-e19.
36. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannenschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. 2001. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res 89: 47-54.
37. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. MiRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-144.
38. Haddad JJ, Land SC. 2001. A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α. FEBS Lett 505: 269-274.
39. Hägele S, Kühn U, Böning M, Katschinski DM. 2009. Cytoplasmic polyadenylation-element-binding protein (CPEB)1 and 2 bind to the HIF-1alpha mRNA 3'-UTR and modulate HIF-1alpha protein expression. Biochem J 417: 2235-2246.
40. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Armheiter H, Copeland NG, Jenkins NA, Fisher DE. 1994. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8: 2770-2780.
41. Hinman MN, Lou H. 2008. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 65: 3168-3381.
42. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. 2004. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104: 2746-2751.
43. Huang LE, Gu J, Schau M, Bunn HF. 1998. Regulation of hypoxia-inducible factor 1a is mediated by an O2-dependent degradation domain via the ubiquitin proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992.
44. Huang X, Ding L, Bennewith KL, Tong R, Ang KK, Story M, Le QT, Giaccia AJ. 2009. Hypoxia-inducible mir-210 regulates normoxic expression involved in tumor initiation. Mol Cell 35: 856-867.
45. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H, Katano M. 2009. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 100: 725-731.
46. Isoe T, Makino Y, Mizumoto K, Sakagami H, Fujita Y, Honjo J, Takiyama Y, Itoh H, Haneda M. 2010. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int 78: 48-59.
47. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. 2002. Regulation and destabilization of HIF-1 alpha by ARD1-mediated acetylation. Cell 111: 709-720.
48. Jiang Y, Wu J, Keep RF, Hua Y, Hoff JT, Xi G. 2002. Hypoxia-inducible factor-1α accumulation in the brain after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 22: 689-696.
49. Kallio PJ, Willson WJ, O'Brien S, Makino Y, Poellinger L. 1999. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525.
50. Karin M, Greten FR. 2005. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759.
51. Ke Q, Costa M. 2006. Hypoxia-inducible factor -1 (HIF-1). Mol Pharmacol 70: 1469-1480.
52. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. 2006. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859-3868.
53. Kim J, Shao Y, Kim SY, Kim S, Song HK, Jeon JH, Suh HW, Chung JW, Yoon JR, Kim YS, Choi I. 2008. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1α expression through a Rac1-dependent NF-kB pathway. Mol Biol Cell 19: 433-444.
54. King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. 1999. Microphthalmia transcription factor: A sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 155: 731-738.
55. Knüpfer H, Preiss R. 2010. Serum interleukin-6 levels in colorectal cancer patients - A summary of published results. Int J Colorectal Dis 25: 135-140.
56. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, Tanaka M. 2000. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kB activation. Oncogene 19: 1225-1231.
57. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, Hoon DSB. 2006. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 12: 1137-1143.
58. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. 2007. A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
59. Kulshreshtha R, Duvuluri RV, Calin GA, Ivan M. 2008. A mircoRNA component of the hypoxic response. Cell Death Differ 15: 667-671.
60. Kung JW, Currie IS, Forbes SJ, Ross JA. 2010. Liver development, regeneration and carcinogenesis. J Biomed Biotechnol (Article ID 984248: 8 pages)., DOI: 10.1155/2010/984248.
61. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, Whiteside TL. 2003. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97: 1015-1024.
62. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. 2002a. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 295: 858-861.
63. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. 2002b. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471.
64. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
65. Lee E, Yim S, Lee SK, Park H. 2002. Two transactivation domains of hypoxia-inducible factor-1 alpha regulated by the MEK-1/p42/p44 MAPK pathway. Mol Cells 14: 9-15.
66. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. 2004. Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp Mol Med 36: 1-12.
67. Levy C, Khaled M, Fisher DE. 2006. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12: 406-414.
68. López-Lázaro M. 2009. Role of oxygen in cancer: Looking beyond hypoxia. Anticancer Agent Med Chem 9: 517-525.
69. Mahon PC, Hirota K, Semenza GL. 2001. FIH-1: A novel protein that interacts with HIF-1 alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686.
70. Matsumoto K, Nakamura T. 2006. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119: 477-483.
71. Maxwell PH. 2005. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 90: 791-797.
72. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE. 2002. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718.
73. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. 2004. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64: 509-516.
74. Minet E, Ernest I, Michel G, Roland I, Remacie J, Raes M, Michiels C. 1999. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5'UTR. Biochem Biophys Res Commun 261: 534-540.
75. Mousa SA. 2002. Anticoagulants in thrombosis and cancer: The missing link. Semin Thromb Hemost 28: 45-52.
76. Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S. 2002. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 173: 315-323.
77. Nierodzik ML, Karpatkin S. 2006. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10: 355-362.
78. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D. 2008. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205: 585-594.
79. Pagé EL, Robitaille GA, Pouysségur J, Richard DE. 2002. Induction of hypoxia-inducible Factor-1α by transcriptional and translational mechanisms. J Biol Chem 277: 48403-48409.
80. Pagé EL, Chan DA, Giaccia AJ, Levine M, Richard DE. 2008. Hypoxia-inducible factor-1α stabilization in nonhypoxic conditions: Role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 19: 86-94.
81. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. 2008. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19: 353-358.
82. Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel E. 2008. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and β1-integrin on the cell surface. J Biol Chem 283: 2822-2834.
83. Ramadori P, Ahmad G, Ramadori G. 2010. Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute phase response: A role for IL-6. Lab Invest 90: 1306-1324.
84. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF, Abdellatif M. 2009. Downregulation of Mir199a depresses hypoxia-inducible factor-1α and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104: 879-886.
85. Richard DE, Berra E, Gothie E, Roux D, Pouysségur J. 1999. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1 alpha (HIF-1 alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637.
86. Richard DE, Berra E, Pouysségur J. 2000. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vasular smooth muscle cells. J Biol Chem 275: 26765-26771.
87. Richard DE, Vouret-Craviari V, Pouysségur J. 2001. Angiogenesis and G-protein-coupled receptors: Signals that bridge the gap. Oncogene 20: 1556-1562.
88. Rickles FR, Edwards RL. 1983. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14-31.
89. Rickles FR, Patierno S, Fernandez PM. 2003. Tissue factor, thrombin, and cancer. Chest 124: 58S-68S.
90. Riedel F, Zaiss I, Herzog D, Götte K, Niam R, Hörmann K. 2005. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 25: 2761-2765.
91. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. 2008. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453: 807-811.
92. Scheringa M, Marquet RL. 1990. TNF: A brief review with emphasis on its antitumor activity. Biotherapy 2: 275-281.
93. Semenza GL. 2000. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480.
94. Semenza GL. 2010a. Vascular responses to hypoxia and ischemia. Artherioscler Thromb Vasc Biol 30: 648-652.
95. Semenza GL. 2010b. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
96. Semenza GL, Wang GL. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454.
97. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. 1990. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171: 35-47.
98. Shibahara S, Takeda K, Yasumoto K, Udono T, Watanabe K, Saito H, Takahashi K. 2001. Microphthalmia-associated transcription factor (MITF): multiplicity in structure, function, and regulation. J Investig Dermatol Symp Proc 6: 99-104.
99. Shweiki D, Neeman M, Itin A, Keshet E. 1995. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci 92: 768-772.
100. Snyder KM, Kessler CM. 2008. The pivotal role of thrombin in cancer biology and tumorigensis. Semin Thromb Hemost 34: 734-741.
101. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. 2000. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1 alpha. Cancer Res 60: 4873-4880.
102. Steingrimsson E, Copeland NG, Jenkins NA. 2004. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 38: 365-411.
103. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutan S, Kikkawa F. 2005. Functional expression of the angiotensin II type1receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11: 2686-2694.
104. Sun N, McAfee W, Hum G, Weiner J. 1979. Hemostatic abnormalities in malignancy, a prospective study in one hundred and eight patients. Coagulation Studies. Am J Clin Pathol 71: 10-16.
105. Tacchini L, Dansi P, Matteucci E, Desiderio MA. 2001. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22: 1363-1371.
106. Tacchini L, dePonti C, Matteucci E, Follis R, Desiderio MA. 2004. Hepatocyte growth factor-activated NF-kB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25: 2089-2100.
107. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T. 2008. Identification of hypoxia-inducible factor-1α as a novel target for miR-17-92 MicroRNA Cluster. Cancer Res 68: 5540-5545.
108. Thews O, Kelleher DK, Vaupel P. 2000. Disparate responses of tumour vessels to angiotensin II: Tumour volume-dependent effects on perfusion and oxygenation. Br J Cancer 83: 225-231.
109. Thrash-Bingham CA, Tartof KD. 1999. aHIF: A natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 91: 143-151.
110. Tojo M, Matsuzaki K, Minami T, Honda Y, Yasuda H, Chiba T, Saya H, Fujii-Kuriyama Y, Nakao M. 2002. The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. J Biol Chem 277: 46576-46585.
111. Trousseau A. 1865. Phlegmasia alba dolens. Clinique Medicale de l'Hôtel-Dieu de Paris, Vol. 3. London: New Sydenham Society. pp. 94-96.
112. Tug S, Delos Reyes B, Fandrey J, Berchner-Pfannenschmidt U. 2009. Non-hypoxic activation oft he negative feedback-loop of prolyl-hydroxylase oxygen sensors. Biochem Biophys Res Commun 384: 519-523.
113. van Horssen R, Ten Hagen TL, Eggermont AM. 2006. NF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408.
114. van Uden P, Kenneth NS, Rocha S. 2008. Regulation of hypoxia-inducible factor-1α by NF-kB. Biochem J 412: 477-484.
115. Varki NM, Varki A. 2002. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: Rationale for clinical studies in humans. Semin Thromb Hemost 28: 53-66.
116. Vaupel P, Mayer A. 2007. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
117. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello CA. 2006. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25: 417-434.
118. Vilcek J, Lee TH. 1991. Minireview tumor necrosis factor: New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266: 7313-7316.
119. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNAs expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261.
120. Wallenius V, Hisaoka M, Helou K, Levan G, Mandahl N, Meis-Kindblom JM, Kindblom LG, Jansson JO. 2000. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human muscuskeletal tumors. Am J Pathol 156: 821-829.
121. Westra J, Brouwer E, vanRoosmalen IA, Doombos-van der Meer B, vanLeuwen MA, Posthumus MD, Kallenberg CG. 2010. Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord 11: 61. DOI: 10.1186/1471-2474-11-61
122. Wheeler GP, Bennett LL Jr. 1962. Studies related to the mode of action of actinomycin D. Biochem Pharmacol 11: 353-370.
123. Wiener CM, Booth G, Semenza GL. 1996. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225: 485-488.
124. Wu Y, Zhou BP. 2010. TNF-α/NF-kB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102: 639-644.
125. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T. 2004. Correlation bewteen interleukin 6 production and tumor proliferation in non-samll cell lung cancer. Cancer Immunol Immunother 53: 786-792.
126. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ. 2010. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis Proc Natl Acad Sci USA 107: 6334-6339.
127. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T, Imura H. 1990. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170: 223-230.
128. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. 1994. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 14: 8058-8070.
129. Yoda Y, Abe T. 1981. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 46: 706-709.
130. Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE. 2008. Pharmacologic suppression of MITF expression via HDAY inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21: 457-463.
131. Yu AY, Frid MG, Shimonda LA, Wiener CM, Stenmark K, Semenza GL. 1998. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275 (4 Pt 1): 818-826.
132. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. 1998. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J 17: 5085-5094.
133. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S. 2010. Angiotensin II/angiotensin II type i receptor (AT1R) signaling promotes MCF-7 breast cancer cell survival via PI3-kinase/Akt pathway. J Cell Physiol 225: 168-173.